Two cases of anti-glomerular basement membrane disease with IgA nephropathy and literature review

Li Xiaohua, Wei Meiju, Yang Zhenhua, Pan Ling

PDF(935 KB)
Chinese Journal of Nephrology ›› 2025, Vol. 41 ›› Issue (1) : 31-37. DOI: 10.3760/cma.j.cn441217-20240731-00748
IgA Nephropathy

Two cases of anti-glomerular basement membrane disease with IgA nephropathy and literature review

Author information +
History +

Abstract

Objective To report two cases of anti-glomerular basement membrane (GBM) disease with IgA nephropathy (IgAN), and summarize the clinical characteristics of these patients through systematic literature review, for providing clinical data for the diagnosis and treatment of this disease. Methods It was a case-series analysis. Clinical data of two cases with anti-GBM disease and IgAN diagnosed in the First Affiliated Hospital of Guangxi Medical University were collected. The course of their diagnosis and treatment was described. Besides, the relevant literature of anti-GBM disease with IgAN cases reported in PubMed and CNKI databases from the establishment of the database to June 30, 2024 were retrived, and the relevant clinical data were extracted for analysis and summary. Patients were divided into end⁃stage renal disease (ESRD) group and non-ESRD group according to renal outcome, and the differences in age, gender, hemoglobin, creatinine at diagnosis, proportion of hypuria/anuria, qualitative grade of urinary protein, and proportion of renal crescent were compared between the two groups. Results Two patients were both young women. The pathology of renal tissue suggested crescentic glomerulonephritis. The pathological manifestations were linear deposition of IgG along GBM and deposition of immune complex dominated by IgA in mesangial region. At the initial diagnosis, the renal function damage of the case one was not severe. After plasma exchange, glucocorticoid and cyclophosphamide treatment, the renal function recovered. The kidney function of the case two was obviously impaired at the initial diagnosis, and was improved after the above treatment, but aggravated due to infection, and continued to progress into ESRD. Twenty-six literates involving 40 cases of anti-GBM disease with IgAN were retrieved. A total of 42 cases of anti-GBM disease with IgAN, including 2 cases in this report, were analyzed and summarized. The age was (41.3±17.5) years old, 45.2% were male, 39 cases (92.9%) were from Asia. The hemoglobin was (94.4±15.1) g/L, the serum creatinine was 450.8 (284.4, 755.8) μmol/L, 83.3% (35/42) patients had crescent ratio greater than 50% and 37 patients (88.1%) patients were treated with intravenous methylprednisolone and cytotoxic immunosuppressive drugs. Plasma exchange was performed in 34 patients (81.0%) patients, 23 patients (54.8%) had renal function recovered and 17 patients (40.5%) entered ESRD. Compared with the non-ESRD group, the serum creatinine in the ESRD group was higher at initial diagnosis (P<0.01), and the proportion of hypuria/anuria was higher (P=0.03). There were no statistically significant differences in age, sex, hemoglobin, urinary protein and crescent proportion between the two groups (all P>0.05). Conclusions Compared with anti-GBM disease, anti-GBM with IgAN has a smoother course and a better prognosis. Infection should be actively prevented during treatment.

Key words

Anti-glomerular basement membrane disease / Glomerulonephritis, IgA / Prognosis

Cite this article

Download Citations
Li Xiaohua. , Wei Meiju. , Yang Zhenhua. , Pan Ling. Two cases of anti-glomerular basement membrane disease with IgA nephropathy and literature review[J]. Chinese Journal of Nephrology, 2025, 41(1): 31-37. DOI: 10.3760/cma.j.cn441217-20240731-00748.
抗肾小球基底膜(glomerular basement membrane,GBM)病是一种少见的、由血液循环自身抗体介导的免疫性疾病,主要表现特征为外周血抗GBM自身抗体阳性和/或肾脏免疫病理表现为IgG沿肾小球基底膜呈线性沉积,主要受累器官为肾脏和肺,临床多表现为急进性肾小球肾炎(rapidly progressive glomerulonephritis,RPGN),部分患者可出现严重肺泡出血,严重者危及生命。近年来,越来越多的非典型抗GBM病例被报道,提示该疾病的异质性1,其中,同时合并其他类型的肾小球疾病在肾活检中并不罕见,但抗GBM病合并IgA肾病(IgA nephropathy,IgAN)的病例报道尚不多见。我们报道2例抗GBM病合并IgAN的病例,并系统性复习相关文献,总结此类病例的临床病理表现特点及预后,以期为该病的诊治提供临床经验。

病例资料

一、 病例报告

1.病例1,女,16岁,因“反复颜面、双下肢水肿1个月余”于2023年11月8日入住广西医科大学第一附属医院肾内科。患者2023年10月初出现颜面及双下肢水肿,无发热、胸闷、气促,无咳嗽、咯血,无关节痛及皮疹。当地医院就诊,经抗感染、利尿治疗后水肿消退,两周后水肿症状复发且加重。入住当地医院查血肌酐(serum creatinine,Scr)71 μmol/L,尿白细胞(±),尿蛋白(3+),尿红细胞(3+),24 h尿蛋白量5.02~6.83 g,2次测血抗GBM抗体(+)。2023年10月31日在外院接受肾穿刺活检,光镜下见16个肾小球,3个大细胞性、2个大细胞纤维性、3个小细胞性及1个小细胞纤维性新月体形成,1个肾小球毛细血管袢节段性坏死,余肾小球系膜细胞和基质轻⁃中度增生,局灶节段性加重伴内皮细胞增生,基底膜无增厚,系膜区嗜复红蛋白沉积,肾小球基底膜上皮下、内皮下无明显嗜复红蛋白沉积。肾小管上皮细胞空泡变性,部分肾小管管腔扩张,可见部分肾小管上皮脱落、刷毛缘消失,肾小管无明显萎缩,肾间质有少量炎细胞浸润,无明显纤维化,小动脉管壁无明显病变。免疫荧光检查示:IgA(3+)、C3(2+)和IgM(1+)沿系膜区团块状沉积,IgG(3+)沿毛细血管袢线状沉积,肾小球坏死区域Fib(+),KM55(+),C1q(-),Alb(-),肾小管重吸收小滴Alb(+),蛋白管型IgA(+)。电镜检查:见2个新月体形成的肾小球,肾小球毛细血管袢部分受压,壁层细胞增生,新月体形成,基底膜无明显增厚(200~320 nm),脏层上皮细胞空泡变性,足突无弥漫融合,可见节段性融合,肾小球基底膜上皮下、基底膜内和内皮下未见电子致密物沉积,系膜细胞和基质增生,系膜区可见电子致密物沉积。肾小管上皮细胞空泡变性,肾间质见散在炎细胞浸润。病理诊断:符合抗GBM病合并IgAN,IgAN牛津分型评分:M1E1S0T0C2。见图1。当地医院诊断:(1)抗GBM病;(2)IgAN。行血浆置换3次,甲泼尼龙500 mg×3 d冲击后予40 mg每日一次口服维持及对症支持等治疗,但Scr从正常升至170 μmol/L,尿量减少,为进一步诊治遂转至本院。患者既往史、个人史及家族史未见异常。入院查体:体温36.5 ℃,血压121/80 mmHg,查体心肺腹(-),双下肢对称性凹陷性水肿。实验室检查:血红蛋白(hemoglobin,Hb)101 g/L,血白蛋白(albumin,Alb)22.5 g/L,Scr 170 μmol/L,补体C3 0.782 g/L,补体C4 0.147 g/L,IgA 1.17 g/L,抗GBM⁃IgG 16.7 AU/ml(正常值<20 AU/ml),尿红细胞(3+),尿蛋白(3+),24 h尿蛋白量2.12 g(尿量700 ml/24 h),降钙素原0.499 μg/L,C反应蛋白、血沉、抗核抗体谱3项、抗中性粒细胞胞质抗体(anti⁃neutrophilic cytoplasmic antibody,ANCA)及血免疫固定电泳未见异常。腹部B超检查:左肾大小约13.1 cm×5.9 cm×5.9 cm,实质厚2.0 cm;右肾大小约13.6 cm×6.4 cm×6.0 cm,实质厚1.8 cm。肾实质回声增强,均匀,皮髓质分界不清,集合管系统与肾实质分界不清,左肾静脉受压声像。胸部CT检查:(1)两侧胸腔和心包少量积液;(2)腹水(少量);(3)胸、腹壁水肿。入院后予甲泼尼龙20 mg每日一次、环磷酰胺(cyclophosphamide,CTX)0.4 g(分两天给药)冲击治疗,共予以CTX 2次冲击治疗(累积剂量0.8 g),同时予利尿、护肾、护胃、调脂及补钙等治疗,治疗后复查Scr 163 μmol/L,Alb 20.3 g/L,Hb 91.5 g/L,水肿消退,一般情况可,无特殊不适,于2023年11月13日病情好转出院。出院后门诊予以甲泼尼龙20 mg每日一次+CTX 50 mg每日一次免疫抑制治疗,2023年12月8日门诊随访Scr 116 μmol/L,Alb 29 g/L,Hb 101 g/L,抗GBM抗体8.28 AU/ml,肾功能较前恢复。最后1次随访时间为2024年7月18日,查血肌酐62 μmol/L,抗GBM抗体<2 AU/ml。
图1 病例1肾组织病理改变
注:A:新月体形成(PAS ×400);B:IgG弥漫、球性沿毛细血管袢呈线状沉积(免疫荧光 ×400);C:系膜区IgA呈团块状沉积(免疫荧光 ×400);D:足突节段融合,系膜基质增多,系膜区可见团块状电子致密物沉积(电镜 ×8 000)

Full size|PPT slide

2.病例2,女,20岁,因“双下肢水肿两周”于2023年6月26日入院。患者入院两周前无明显诱因出现双下肢水肿,无畏寒、发热,无咳嗽、咳痰、咯血,无关节痛及皮疹,至当地医院就诊,查血压145/100 mmHg,Scr 286 μmol/L,尿酸424 μmol/L,Hb 86 g/L,Alb 22.9 g/L,血抗GBM抗体(+),脑利钠肽前体2 380 ng/L,尿蛋白(3+)。2023年6月20日外院肾穿刺活检:光镜下见20个肾小球,4个肾小球球性硬化,未见节段性硬化,6个肾小球大细胞纤维性新月体形成,3个肾小球小细胞纤维性新月体形成,余肾小球系膜细胞和基质轻中度增生,局灶节段性加重性内皮细胞增生,基底膜无增厚,系膜区嗜复红蛋白沉积,肾小球基底膜上皮下、内皮下无明显嗜复红蛋白沉积。肾小管上皮空泡变性,可见蛋白管型,部分肾小管管腔扩张及上皮细胞脱落,刷毛缘消失,部分肾小管萎缩(萎缩面积约35%),肾间质多灶状炎细胞浸润伴纤维化,小动脉管壁增厚及部分管腔狭窄。免疫荧光检查:IgG(3+)沿毛细血管袢线状沉积,IgA(2+)、IgM(1+)及C3(1+)沿系膜区团块状沉积,C1q、Fib及Alb均阴性,KM55(-)。肾小管重吸收小滴Alb阳性,蛋白管型IgA阳性,小动脉壁C3阳性。电镜检查:见1个硬化的肾小球,肾小球毛细血管袢闭塞,基质增生,肾小管萎缩,肾间质炎细胞浸润伴纤维化。见图2。病理诊断:抗GBM病合并IgAN的新月体肾炎;IgAN牛津分型M1E1S1T1C2。当地医院予利尿等治疗后水肿无好转,尿量减少,遂转至本院就诊。既往史、个人史及家族史无特殊。入院时体温36.5 ℃,血压142/106 mmHg,心肺腹(-),双下肢凹陷性水肿。实验室检查:Hb 78.00 g/L,Alb 24.7 g/L,Scr 389 μmol/L,C反应蛋白9.0 mg/L,尿红细胞(3+),尿蛋白(3+),IgA 1.99 g/L,IgG 6.93 g/L,IgM 2.62 g/L,抗髓过氧化物酶(myeloperoxidase,MPO)⁃IgG 24.80 AU/ml(正常值<20 AU/ml),抗中性粒细胞胞质抗体(p⁃ANCA)阴性;抗GBM⁃IgG 40.70 AU/ml,24 h尿蛋白量856.5 mg,24 h尿量300 ml。血免疫固定电泳未见异常。B超检查:右肾大小9.9 cm×4.2 cm,左肾大小10.1 cm×5.1 cm,双肾实质回声增强,双侧肾动脉血流速度降低,左肾静脉未见受压声像。胸部CT检查:(1)右肺中叶内侧段、左肺下叶后基底段轻度炎症;(2)右肺上叶尖段纯磨玻璃结节,考虑炎性结节;(3)两侧胸腔少量积液。入院后予血浆置换2次,甲泼尼龙500 mg×3 d冲击治疗后改为40 mg每日一次维持,CTX 0.4 g分两天给药,共冲击治疗2次(累积剂量0.8 g),同时予利尿、降压、碱化尿液、护肾、抑酸护胃和对症支持等治疗。2023年7月6日复查抗GBM⁃IgG 13.50 AU/ml,恢复至正常范围,Hb 78.00 g/L,Scr 416 μmol/L,Alb 20.9 g/L,水肿有所好转,于2023年7月7日出院。出院后定期门诊随诊,甲泼尼龙从40 mg开始规律减量,CTX每月静脉冲击治疗1次(累积剂量2.8 g),多次复查抗GBM抗体均为阴性,Scr曾降至276 μmol/L。2023年10月呼吸道感染后诱发肾功能恶化,水肿复发,2023年11月10日查Scr 415 μmol/L,2023年12月12日复查Scr 547 μmol/L,2023年12月14日复查抗GBM抗体(-),2024年2月复查肌酐升至708 μmol/L,尿蛋白(3+),因肾功能恶化至终末期肾病(end⁃stage renal disease,ESRD),予长期维持性血液透析治疗,至末次随访时间2024年5月20日均在本院接受规律透析治疗。
图2 病例2肾组织病理改变
注:A:新月体形成(PAS ×400);B:IgG弥漫、球性沿毛细血管袢呈线状沉积(免疫荧光 ×400);C:系膜区IgA呈团块状沉积(免疫荧光 ×400);D:细胞纤维性新月体,系膜细胞及基质轻中度增生,肾小管刷状缘脱落,部分肾小管萎缩,间质纤维化,间质有较多炎细胞浸润(Masson ×400)

Full size|PPT slide

二、 文献复习

使用英文关键词“anti⁃GBM disease”“anti⁃GBM nephritis”“anti⁃GBM glomerulonephritis”“IgA nephropathy”,中文关键词“抗GBM病”“抗肾小球基底膜病”与“IgA肾病”组合分别检索了PubMed、CNKI数据库自建库至2024年6月30日有关抗GBM病合并IgAN病例报道的相关文献26篇共40例,由两位作者分别独立阅读全文,提取相关临床数据,回顾性分析和总结了包括本中心的2例在内共42例抗GBM病合并IgAN病例。42例患者年龄(41.3±17.5)岁,男性占比45.2%。在地域分布上,中国31例、日本3例、美国1例、澳大利亚2例、韩国1例、印度4例,病例大多来自亚洲,且主要来自东亚。42例患者Hb(94.4±15.1)g/L,血肌酐450.8(284.4,755.8)μmol/L,35例(83.3%)患者新月体比例>50%,37例(88.1%)患者静脉用甲泼尼龙及细胞毒药物免疫抑制治疗,34例(81.0%)患者接受过血浆置换治疗,23例(54.8%)患者肾功能恢复良好。为进一步探讨此类患者肾脏预后不良的危险因素,根据患者是否进入ESRD期分为ESRD组和非ESRD组,比较两组患者年龄、性别、血红蛋白、诊断时血肌酐、少尿和/或无尿比例、尿蛋白定性等级、肾脏新月体比例的差异,结果显示,ESRD组患者初诊血肌酐高于非ESRD组(t=-3.70,P<0.01)、少尿和/或无尿比例高于非ESRD组(χ 2=4.54,P=0.03),两组在年龄、性别、贫血、蛋白尿定性等级和新月体比例等项目上的差异均无统计学意义(均P>0.05)。见表1
表1 42例抗GBM病合并IgAN患者中ESRD组与非ESRD组患者临床指标的比较
项目 ESRD组(n=17) 非ESRD组(n=25) t/Z/χ 2 P
年龄(岁) 45.8±16.1 38.4±18.1 0.06 0.19
血红蛋白(g/L) 93.7±1.6 94.9±1.5 0.60 0.80
诊断时血肌酐(μmol/L) 751.4(556.9,890.6) 318.2(207.7,486.5) -3.70 <0.01
少尿/无尿[例(%)] 4.54 0.03
8(66.7) 6(28.6)
4(33.3) 15(71.4)
性别[例(%)] 2.13 0.15
10(58.8) 9(36.0)
7(41.2) 16(64.0)
尿蛋白定性[例(%)] -0.87 0.38
1+ 3(20.0) 6(24.0)
2+ 3(20.0) 8(32.0)
3+ 6(40.0) 8(32.0)
4+ 3(20.0) 3(12.0)
肾脏病理新月体>50%[例(%)] <0.01 0.99
14(87.5) 21(87.5)
2(12.5) 3(12.5)
注:GBM:抗肾小球基底膜;IgAN:IgA肾病;ESRD:终末期肾病;数据形式除已注明外,正态分布的计量资料以x-±s形式表示,非正态分布的计量资料以MQ 1Q 3)形式表示,计数资料以例数(百分比)表示

讨 论

该文报道了广西医科大学第一附属医院诊治的2例抗GBM病合并IgAN患者临床资料,2例患者均为年轻女性,起病急,临床表现为水肿、血尿、蛋白尿及肾功能异常,并呈现肾病综合征表现,均有尿量减少,例2达到少尿状态,且肾损害表现更为明显。2例患者肾脏病理均表现为抗GBM病合并IgA沉积的新月体肾炎。2例患者入院后均接受了血浆置换、糖皮质激素及环磷酰胺冲击治疗,抗GBM抗体均转阴。至末次随访时间,例1肾功能恢复正常,例2肾功能曾一度好转,但病程中反复出现呼吸道感染,最终肾功能恶化进展至ESRD需接受长期透析治疗。
为了更好地了解抗GBM病合并IgAN的临床特点、病理改变特征及预后情况,我们检索了PubMed、中国知网数据库自建库至2024年6月30日发表的关于抗GBM病合并IgAN的病例报道共40例2-26,并回顾性分析和总结了包括本中心的2例在内共42例抗GBM病合并IgAN病例资料。42例患者年龄13~76岁,符合抗GBM病的经典双峰分布27。在地域分布上,病例大多来自亚洲,且主要来自东亚,反映了IgAN患病率的地区和种族差异,35例(83.3%)患者新月体比例>50%,37例(88.1%)患者静脉用甲泼尼龙及细胞毒药物免疫抑制治疗,34例(81.0%)患者采用了血浆置换治疗,23例(54.8%)患者肾功能恢复良好,提示抗GBM病合并IgAN患者的病程较单纯抗GBM病平缓,预后较好,与目前报道的抗GBM病合并其他类型肾小球疾病肾脏预后不同。有文献报道,抗GBM病合并ANCA相关性血管炎的患者多数表现为急进性肾衰竭,肾存活率低,多数患者发展至ESRD28。值得注意的是,该研究中的例2患者MPO阳性,p⁃ANCA阴性,免疫荧光检查示以IgA沉积为主且伴IgG及IgM肾组织沉积,诊断血管炎依据尚不足,目前多数文献报道ANCA、抗GBM抗体双阳性患者预后较经典的单纯抗GBM病更差29,例2患者MPO阳性,但这也不能除外是其肾脏预后差的原因。有研究报道,抗GBM病合并膜性肾病的患者肾脏预后也较差,即使及时予以血浆置换和免疫抑制治疗,肾脏预后仍然不容乐观30
既往的研究结果显示,高龄、低肾小球滤过率、低血红蛋白、高新月体比值、初诊时Scr水平较高为抗GBM病预后不良的危险因素31-32。在我们收集的42例抗GBM病合并IgAN病例中,有17例进展至ESRD。为进一步探讨此类患者肾脏预后不良的危险因素,我们根据患者是否进入ESRD分为ESRD组和非ESRD组,两组临床资料的比较结果显示,ESRD组患者初诊Scr水平、少尿和/或无尿比例显著高于非ESRD组,两组在年龄、性别、血红蛋白、蛋白尿和新月体比例等临床指标的差异均无统计学意义。
目前抗GBM病合并IgAN预后相对较好的具体机制并不明确。抗GBM抗体的主要靶抗原识别Ⅳ型胶原α3链内的构象表位,有研究者发现,抗α3(Ⅳ)Nc1自身抗体水平是初诊时血肌酐水平较高的独立危险因素,抗α1、α2、α4和α5链的自身抗体对肾损害的影响小于α3链。而一项关于IgAN的研究发现,α5(Ⅳ)Nc1在GBM的垂直切面呈明显的线性沉积,在有新月体形成的肾小球中,GBM断裂,GBM抗原暴露,从而产生抗GBM自身抗体33。上述研究结果显示,不同α链表位可能部分解释了抗GBM合并IgAN预后较好的原因。近年来,抗GBM病合并IgAN的发病机制受到越来越多研究者关注。Kojima等4报道了1例IgAN疾病过程中发生抗GBM病,作者认为抗GBM病可能继发于IgAN,并提出IgA相关免疫复合物可能促进免疫和炎性反应的假说,导致GBM抗原构象发生改变和暴露,从而产生抗GBM的自身抗体。此外,有研究表明,半乳糖缺陷型IgA1(galactose deficient,Gd⁃IgA1)抗体的沉积导致新的GBM抗原形成,从而触发自身免疫反应,引起抗GBM抗体的产生2。然而,由于尚未发现区分原发性和继发性抗GBM病的生物标志物,因此很难证明此类患者的抗GBM病是偶然并发症还是继发于IgAN。本研究中病例1免疫荧光检查示Gd⁃IgA1特异性抗体KM55阳性,既往有研究发现,IgAN合并膜性肾病时,KM55阳性的患者预后往往较差34,但其对抗GBM病合并IgAN患者预后的影响尚不清楚。
抗GBM病合并IgAN患者往往存在免疫功能低下,血浆置换、激素冲击及免疫抑制剂的应用会增加机会性感染的概率。有研究者报道了1例抗GBM病合并IgAN患者治疗过程中出现卡氏肺孢子菌肺部感染,经复方磺胺甲噁唑等药物积极抗感染治疗后疾病缓解5。本研究中例2患者经积极治疗一度肾功能好转,抗GBM抗体恢复阴性,但因反复呼吸道感染引起肾功能恶化,最终进展至ESRD,需接受长期肾脏替代治疗。提示此类患者在使用激素及免疫抑制剂治疗过程中需积极预防感染,如感染发生应尽早明确感染灶及进行病原学检查,针对性地制订治疗措施,这对改善患者预后非常重要。
综上,我们报道了2例抗GBM病合并IgAN病例,并通过复习相关文献,总结了42例抗GBM病合并IgAN患者的临床病理特点和预后情况。但本研究尚存在一定的局限性,如病例数量及可供分析的数据有限;尿蛋白检查仅以尿蛋白定性划分等级,未纳入尿蛋白定量等。通过对42例患者临床资料的分析总结,我们发现,尽管抗GBM病合并IgAN总体上可能比单纯抗GBM病的肾脏预后较好,但仍然为一种快速进展的疾病,早期病理诊断和及时免疫抑制治疗是患者获得良好预后的关键,治疗过程中积极预防感染也非常重要。今后需要进一步深入研究抗GBM病与IgAN之间的潜在相关关系及发病机制,为此类疾病的治疗提供更精准化的措施和方案。

References

1
Bharati J, Yang Y, Sharma P, et al. Atypical anti-glomerular basement membrane disease[J]. Kidney Int Rep, 2023, 8(6): 1151-1161. DOI: 10.1016/j.ekir.2023.03.010 .
2
Cui Z, Zhao MH, Wang SX, et al. Concurrent antiglomerular basement membrane disease and immune complex glomerulonephritis[J]. Ren Fail, 2006, 28(1): 7-14. DOI: 10.1080/08860220500461195 .
3
Shen CR, Jia XY, Cui Z, et al. Clinical and immunological characteristics of patients with combined anti-glomerular basement membrane disease and IgA nephropathy[J]. Clin Kidney J, 2023, 16(9): 1480-1488. DOI: 10.1093/ckj/sfad068 .
4
Kojima T, Hirose G, Komatsu S, et al. Development of anti-glomerular basement membrane glomerulonephritis during the course of IgA nephropathy: a case report[J]. BMC Nephrol, 2019, 20(1): 25. DOI: 10.1186/s12882- 019-1207-3 .
5
Zhang M, Yang D, Wang W, et al. Pneumocystis pneumonia secondary to intensive immunosuppression treatment for anti-GBM disease complicated with IgA nephropathy: a case report and literature review[J]. Medicine (Baltimore), 2021, 100(45): e27728. DOI: 10. 1097/MD.0000000000027728 .
6
Chen Z, Xu D, Cui F, et al. Coexistence of anti-glomerular basement membrane disease and IgA nephropathy: an illustrative case and comprehensive literature review[J]. Ren Fail, 2024, 46(1): e2323160. DOI: 10.1080/0886022X.2024.2323160 .
7
Matsuno T, Okumura T. Anti-glomerular basement membrane disease after diagnosis of immunoglobulin a nephropathy: a case report[J]. Cureus, 2023, 15(5): e39737. DOI: 10.7759/cureus.39737 .
8
陈雨, 孙妍蓓, 周华, 等. 抗肾小球基底膜病合并IgA肾病1例[J]. 中国临床研究, 2023, 36(5): 758-759+763. DOI: 10.13429/j.cnki.cjcr.2023.05.026 .
9
Guo C, Ye M, Li S, et al. Anti-glomerular basement membrane disease with IgA nephropathy: a case report[J]. World J Clin Cases, 2022, 10(12): 3916-3922. DOI: 10. 12998/wjcc.v10.i12.3916 .
10
Chen H, Jin J, Cheng MJ, et al. High-frequency plasma exchange therapy for immunocompromised, type I crescentic glomerulonephritis complicated with IgA nephropathy: a case report and literature review[J]. Medicine (Baltimore), 2023, 102(3): e32698. DOI: 10. 1097/MD.0000000000032698 .
11
Shaojie F, Sensen S, Jingda H, et al. Great prognosis of concurrent anti-GBM disease and IgA nephropathy in a young woman: a case report[J]. Medicine (Baltimore), 2022, 101(37): e30686. DOI: 10.1097/MD. 0000000000030686 .
12
Bajaj V, Thakur S, Barwad A, et al. IgA nephropathy and atypical anti-GBM disease: a rare dual pathology in a pediatric rapidly progressive glomerulonephritis[J]. Glomerular Dis, 2022, 2(1): 54-57. DOI: 10.1159/000521582 .
13
Khor C, Wong MG, Reagh J. Anti-glomerular basement membrane disease and IgA nephropathy in a patient with previous renal cell carcinoma[J]. BMJ Case Rep, 2021, 14(7): e236555. DOI: 10.1136/bcr-2020-236555 .
14
Malviya PB, Modigonda S, Maitra S, et al. Anti-glomerular basement membrane disease with atypical associations[J]. Saudi J Kidney Dis Transpl, 2021, 32(1): 227-231. DOI: 10.4103/1319-2442.318529 .
15
Suh KS, Choi SY, Bae GE, et al. Concurrent anti-glomerular basement membrane nephritis and IgA nephropathy[J]. J Pathol Transl Med, 2019, 53(6): 399-402. DOI: 10.4132/jptm.2019.08.05 .
16
Longano A. Concurrent anti-GBM disease and IgA glomerulonephritis[J]. Pathology, 2019, 51(3): 336-338. DOI: 10.1016/j.pathol.2018.09.065 .
17
Wang A, Wang Y, Wang G, et al. Mesangial IgA deposits indicate pathogenesis of anti-glomerular basement membrane disease[J]. Mol Med Rep, 2012, 5(5): 1212- 1214. DOI: 10.3892/mmr.2012.809 .
18
单婧, 胡瑞海, 黄志芳, 等. 以腹胀为首发症状的抗肾小球基底膜抗体病合并IgA肾病1例[J]. 人民军医, 2018, 61(3): 265-266. DOI: CNKI:SUN:RMJZ.0.2018-03-022 .
19
高碧霞, 李明喜, 夏文丽, 等. 抗肾小球基底膜病合并IgA肾病1例报告并文献复习[J]. 北京医学, 2009, 31(3): 185- 187. DOI: 10.15932/j.0253-9713.2009.03.017 .
20
Annamalai I, Chandramohan G, Srinivasa PND, et al. Rapidly progressive glomerulonephritis due to anti- glomerular basement membrane disease accompanied by IgA nephropathy: an unusual association[J]. Saudi J Kidney Dis Transpl, 2017, 28(6): 1404-1407. DOI: 10. 4103/1319-2442.220866 .
21
Xu D, Wu J, Wu J, et al. Novel therapy for anti-glomerular basement membrane disease with IgA nephropathy: a case report[J]. Exp Ther Med, 2016, 11(5): 1889-1892. DOI: 10.3892/etm.2016.3149 .
22
王彦, 张丽萍, 杨林, 等. 抗肾小球基膜病合并IgA肾病一例[J]. 中华肾脏病杂志, 2005, 21(9): 501. DOI: 10.3760/j.issn:1001-7097.2005.09.015 .
23
Ge YT, Liao JL, Liang W, et al. Anti-glomerular basement membrane disease combined with IgA nephropathy complicated with reversible posterior leukoencephalopathy syndrome: an unusual case[J]. Am J Case Rep, 2015, 16: 849-853. DOI: 10.12659/ajcr.894619 .
24
Sacker A, Kung V, Andeen N. Anti-GBM nephritis with mesangial IgA deposits after SARS-CoV-2 mRNA vaccination[J]. Kidney Int, 2021, 100(2): 471-472. DOI: 10.1016/j.kint.2021.06.006 .
25
尚伟锋, 王迪, 葛树旺, 等. IgA肾病合并抗肾小球基底膜病病例报告并文献复习[J]. 内科急危重症杂志, 2015, 21(1): 40-43. DOI: 10. 11768/nkjwzzzz20150115 .
26
Yamaguchi H, Takizawa H, Ogawa Y, et al. A case report of the anti-glomerular basement membrane glomerulonephritis with mesangial IgA deposition[J]. CEN Case Rep, 2013, 2(1): 6-10. DOI: 10.1007/s13730- 012-0029-y .
27
Fischer EG, Lager DJ. Anti-glomerular basement membrane glomerulonephritis: a morphologic study of 80 cases[J]. Am J Clin Pathol, 2006, 125(3): 445-450. DOI: 10.1309/nptp-4ukv-7ju3-elmq .
28
Philip R, Dumont A, Martin SN, et al. ANCA and anti- glomerular basement membrane double-positive patients: a systematic review of the literature[J]. Autoimmun Rev, 2021, 20(9): 102885. DOI: 10.1016/j.autrev.2021.102885 .
29
Srivastava A, Rao GK, Segal PE, et al. Characteristics and outcome of crescentic glomerulonephritis in patients with both antineutrophil cytoplasmic antibody and anti- glomerular basement membrane antibody[J]. Clin Rheumatol, 2013, 32(9): 1317-1322. DOI: 10.1007/s10067-013-2268-5 .
30
Bu L, Said SM, Herrera HL, et al. The characteristics of concurrent anti-glomerular basement membrane nephritis and membranous nephropathy[J]. Kidney Int Rep, 2023, 8(10): 2164-2167. DOI: 10.1016/j.ekir.2023. 07.031 .
31
Chen Z, Xu J, Wu J, et al. Prognostic analysis of crescentic glomerulonephritis with acute kidney injury: a single- center cohort with 5-year follow-up[J]. Int Urol Nephrol, 2022, 54(9): 2375-2383. DOI: 10.1007/s11255-022- 03111-w .
32
Cui Z, Zhao J, Jia XY, et al. Anti-glomerular basement membrane disease: outcomes of different therapeutic regimens in a large single-center Chinese cohort study[J]. Medicine (Baltimore), 2011, 90(5): 303-311. DOI: 10. 1097/MD.0b013e31822f6f68 .
33
Masuda Y, Yamanaka N, Ishikawa A, et al. Glomerular basement membrane injuries in IgA nephropathy evaluated by double immunostaining for α5(Ⅳ) and α2(Ⅳ) chains of typeⅣ collagen and low-vacuum scanning electron microscopy[J]. Clin Exp Nephrol, 2015, 19(3): 427-435. DOI: 10.1007/s10157-014-1008-8 .
34
Cheng W, Wang G, Guo W, et al. Glomerular galactose- deficient IgA1 (KM55) positive may predict poorer prognosis in coexisting primary membranous nephropathy and IgA nephropathy patients[J]. Cells, 2022, 12(1): 116. DOI: 10.3390/cells12010116 .

Footnotes

http://journal.yiigle.com/LinkIn.do?linkin_type=cma&DOI=10.3760/cma.j.cn441217-20240731-00748

李晓华:收集病例、文献复习、数据分析和论文撰写;韦美菊:收集病例和数据分析;杨桢华:研究指导和审阅论文;潘玲:研究指导、论文审阅和经费支持

RIGHTS & PERMISSIONS

Copyright by Chinese Medical Association No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission. All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
PDF(935 KB)

212

Accesses

0

Citation

Detail

Sections
Recommended

/